Health Care • Medical Specialities
$73.49 ▼ -0.16
(-0.22%)
MKT CAP: $5.80B • VOL: 571.7K
52W L $51 52W H $86
RDNT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.04B | $1.83B | $1.62B |
| YoY Revenue Growth % | +11.5% | +13.2% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $62.0M | $104.6M | $98.7M |
| Operating Margin % | 3.0% | 5.7% | 6.1% |
| Net Income (GAAP) | -$18.6M | $2.8M | $3.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $298.8M | $233.0M | $220.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | $298.8M | $233.0M | $220.9M |
| FCF Margin % | 14.6% | 12.7% | 13.7% |
| Return on Invested Capital (ROIC %) | 3.5% | 7.2% | — |
| Cash & Short-Term Equivalents | $767.2M | $740.0M | — |
| Total Debt (Short + Long Term) | $1.06B | $991.6M | — |
| Total Stockholders' Equity | $1.09B | $902.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RDNT.